Altered balance between effector T cells and FOXP3 + HELIOS + regulatory T cells after thymoglobulin induction in kidney transplant recipients

Department of Surgery, University of California, San Francisco, CA, USA  Diabetes Center, University of California, San Francisco, CA, USA  California Pacific Medical Center, San Francisco, CA, USA.
Transplant International (Impact Factor: 2.6). 09/2012; 25(12). DOI: 10.1111/j.1432-2277.2012.01565.x
Source: PubMed


This study examined the effect of thymoglobulin induction therapy on leukocyte population dynamics in kidney transplant patients. Patients receiving standard immunosuppression were compared with those who received additional thymoglobulin at the time of kidney transplantation. Thymoglobulin induction led to an immediate and significant decrease of all T cells and NK cells, but not B cells or monocytes. CD8(+) T cells recovered to near pretransplant level by 4 weeks post-transplant. CD4(+) T cells remained at less than 30% of pretransplant level for the entire study period of 78 weeks. Both CD4(+) and CD8(+) T cells showed reduced cytokine production after recovery. Deletion of CD4(+) FOXP3(+) HELIOS(+) regulatory T cells (Tregs) was less profound than that of CD4(+) FOXP3(-) cells, thus the relative percentage of Tregs elevated significantly when compared with pretransplant levels in thymoglobulin-treated patients. In contrast, the percentages of Tregs and their expression of FOXP3 in the standard immunosuppression group decreased steadily and by 12 weeks after transplant the average percentage of Tregs was 56% of the pretransplant level. Thus, thymoglobulin-induced deletion of T cells led to significant and long-lasting alterations of the T-cell compartment characterized by a preservation of Tregs and long-lasting reduction in CD4(+) , and potentially pathogenic, T cells.

Download full-text


Available from: Qizhi Tang, Jan 13, 2015
  • Source
    • "The latter agents inhibit T cell proliferative responses. Both ATG [28] and rapamycin [29] have been considered ''Treg-sparing'' IS agents. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We expanded flow-sorted Foxp3(+) cynomolgus monkey regulatory T cells (Treg) >1000-fold after three rounds of stimulation with anti-CD3 mAb-loaded artificial antigen-presenting cells, rapamycin (first round only) and IL-2. The expanded Treg maintained their expression of Treg signature markers, CD25, CD27, CD39, Foxp3, Helios, and CTLA-4, as well as CXCR3, which plays an important role in T cell migration to sites of inflammation. In contrast to expanded effector T cells (Teff), expanded Treg produced minimal IFN-γ and IL-17 and no IL-2 and potently suppressed Teff proliferation. Following cryopreservation, thawed Treg were less viable than their freshly-expanded counterparts, although no significant changes in phenotype or suppressive ability were observed. Additional rounds of stimulation/expansion restored maximal viability. Furthermore, adoptively-transferred autologous Treg expanded from cryopreserved second round stocks and labeled with CFSE or VPD450 were detected in blood and secondary lymphoid tissues of normal or immunosuppressed recipients at least two months after their systemic infusion. Copyright © 2015 Elsevier Inc. All rights reserved.
    Cellular Immunology 02/2015; 295(1). DOI:10.1016/j.cellimm.2015.02.006 · 1.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Foxp3+ regulatory T cells (Tregs) play a pivotal role in control of autoimmunity and pathologic immune responses. Helios, the Ikarus family transcription factor, binds to the Foxp3 promoter, stabilizing its expression and is expressed in 70% of peripheral Tregs of healthy individuals. This frequency is altered during malignancy, infection and autoimmunity, although the mechanisms that control proliferation and relative numbers of Helios+/- Tregs remain largely unknown. Using a T cell-monocyte in vitro stimulation assay, we now show that proliferation of Helios+ Tregs is inhibited by CD16+ monocyte subset. Antibody blocking with anti-IL-12 reversed this inhibition, whereas addition of IL-12 suppressed Helios+ Treg expansion, indicating that CD16+ monocyte control of Helios+ Treg numbers is mediated through IL-12. In contrast, proliferation of Helios- Tregs, which express higher levels of TNFRII, was suppressed by TNF-α, while anti-TNF-α and anti-TNFRII reversed the inhibition. CD16- monocyte subset was mainly responsible for TNF-α mediated control of Helios- Treg expansion. Altogether, these data suggest a differential role for monocyte subsets in control of Helios +/- Treg development that is mediated by distinct inflammatory cytokines and as such may important implications for understanding the pathogenesis as well as control of chronic inflammatory and autoimmune diseases.
    Blood 01/2013; 121(13). DOI:10.1182/blood-2012-11-469122 · 10.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: T regulatory cells (Tregs) play a critical role in the immunologic tolerance to the graft in transplantation. Thus, due to their immunosuppressive capability, ex vivo expanded Tregs may be used as a cellular therapy and an attractive novel strategy to control chronic rejection and eliminate need for lifelong pharmacological immunosuppression. Since Treg therapy is still in its infancy, initially Tregs still need to be applied in combination with pharmacological agents to prevent rejection. Fortunately, some of the medications have been shown to enhance the function and number of Tregs. In the clinic, different immunosuppressive regimens are used for individual patients for different types of organ transplantation. In this review, we present the most commonly used pharmacological agents for immunosuppression and discuss how they affect the Treg population. It is extremely difficult to dissect the effect of single agent on Tregs population in clinical settings since usually the combination of several medications is applied at the same time for graft protection. Nevertheless, experimental and clinical data indicate that thymoglobulin as immunosuppressive induction and mTOR inhibitors as immunosuppressive maintenance agents have the most beneficial effect on Treg population in the blood. Among supplemental agents promoting Tregs, anti-TNFα preparations have been in clinical use (in autoimmune diseases) for many years, so they are optimal candidates for testing in transplant settings in combination with Treg based cellular therapy.
    International immunopharmacology 03/2013; 16(3). DOI:10.1016/j.intimp.2013.02.015 · 2.47 Impact Factor
Show more